The law firm says buyers of GRAL shares from May 13, 2025 to February 19, 2026 may seek damages tied to alleged misstatements about the NHS-Galleri trial.
Levi & Korsinsky said investors who lost money in Grail, Inc. may be able to recover damages in a securities class action tied to the company's disclosures about its NHS-Galleri registrational trial. The firm said the proposed class period covers purchases of GRAL securities between May 13, 2025 and February 19, 2026, and that the deadline to seek appointment as lead plaintiff is August 4, 2026. The claim centers on allegations that Grail highlighted encouraging trial signals, including a "substantially higher" positive predictive value than the 43% reported in the earlier Pathfinder study, while withholding detailed data and failing to disclose adverse internal trendlines that may have reduced the likelihood of meeting the primary endpoint. The chronology cited by the firm points to several company statements during 2025, including remarks on May 13, August 12, September 9, October 20, and November 12, when management discussed trial progress, statistical powering (designing a study to detect a meaningful result), clinical utility (evidence that a test improves patient outcomes), and supportive Pathfinder 2 data. Levi & Korsinsky alleges those communications did not reveal that a longer follow-up period may have been needed for the three-year study to show a statistically significant reduction in Stage III-IV cancers. Grail disclosed on February 19, 2026 that "the primary endpoint of statistically significant Stage III-IV reduction was not observed," which it attributed to "probably needing a longer follow-up time." Shares fell from $101.53 to $50.21 overnight, a drop of $51.32 per share, or 50.55%. The firm said the case was filed in the United States District Court for the Northern District of California under the Private Securities Litigation Reform Act of 1995. Joseph E. Levi, Esq. said the timeline raises questions about whether adverse findings from internal data reviews should have been disclosed earlier. The release also says investors do not need to take immediate action to remain eligible as class members, and that participation is offered on a contingency basis.